Hal Bar­ron's chase for ge­net­ic clues leads Glax­o­SmithK­line back to neu­ro — and makes new biotech part­ner $700M rich­er overnight

When Glax­o­SmithK­line R&D chief Hal Bar­ron out­lined his vi­sion for the new GSK, he tout­ed re­peat­ed­ly how, dig­ging through func­tion­al ge­nom­ic datasets from part­ners like …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER